HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 141, Issue 1, 2013, Pages 43-53

  Lipton, Allan ^a   Goodman, Laurie ^b,g   Leitzel, Kim ^a   Cook, Jennifer ^b   Sperinde, Jeff ^b   Haddad, Mojgan ^c   Köstler, Wolfgang J ^d   Huang, Weidong ^c   Weidler, Jodi M ^c   Ali, Suhail ^e   Newton, Alicia ^b   Fuchs, Eva Marie ^d   Paquet, Agnes ^c   Singer, Christian F ^f   Horvat, Reinhard ^d   Jin, Xueguang ^b,h   Banerjee, Joyee ^b,i   Mukherjee, Ali ^b,j   Tan, Yuping ^c   Shi, Yining ^b   Chenna, Ahmed ^b   Larson, Jeff ^c   Lie, Yolanda ^c   Sherwood, Thomas ^c,l   Petropoulos, Christos J ^b   Williams, Stephen ^b,k   Winslow, John ^b   Parry, Gordon ^b   Bates, Michael ^c,l   more..

^a PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^b Genentech   (United States)

^c MONOGRAM BIOSCIENCES   (United States)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^g BIODESIX INC   (United States)

^h AGILENT TECHNOLOGIES   (United States)

ⁱ AMGEN INC   (United States)

^j SINGULEX INC   (United States)

^k IntegenX   (United States)

^l CEPHEID   (United States)

more..

Author keywords

Breast cancer; HER2; HER3; p95HER2; Trastuzumab

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN; PROTEIN HER3; PROTEIN P95; PROTEIN P95HER2; PROTEIN TYROSINE KINASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANALYTICAL EQUIPMENT; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TISSUE FIXATION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; COHORT STUDIES; DECISION TREES; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; KAPLAN-MEIER ESTIMATE; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROGNOSIS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RETROSPECTIVE STUDIES; SINGLE-BLIND METHOD; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84884279586     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2665-0     Document Type: Article

References (31)

1. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al (2006) Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820
2. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672
3. Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792
4. Vogel CL, Cobleigh MA, Tripathy D et al (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719-726
5. Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639-2648
6. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684
7. Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 131:18
8. Press MF, Sauter G, Bernstein L et al (2005) Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607
9. Press MF, Slamon DJ, Flom KJ et al (2002) Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095-3105
10. Perez EA, Suman VJ, Davidson NE et al (2006) HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. J Clin Oncol 24:3032-3038
11. Yarden Y (2001) The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3-S8
12. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
13. Ghosh R, Narasanna A, Wang SE et al (2011) Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers. Cancer Res 71:1871-1882
14. Junttila TT, Akita RW, Parsons K et al (2009) Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 15:429-440
15. Lee-Hoeflich ST, Crocker L, Yao E et al (2008) A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res 68:5878-5887
16. Serra V, Scaltriti M, Prudkin L et al (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547-2557
17. Garrett JT, Olivares MG, Rinehart C et al (2009) Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci U S A 108:5021-5026
18. Sergina NV, Rausch M, Wang D et al (2007) Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445:437-441
19. Nagumo Y, Faratian D, Mullen P et al (2009) Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity. Mol Cancer Res 7:1563-1571
20. Makhija S, Amler LC, Glenn D et al (2010) Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol 28:1215-1223
21. Baselga J, Cortes J, Kim SB et al (2011) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366:109-119
22. Gianni L, Bianchini G, Kiermaier A et al (2011) Neoadjuvant pertuzumab (P) and trastuzumab (H): biomarker analyses of a 4-Arm randomized phase II study (NeoSphere) in patients (pts) with HER2-positive breast cancer (BC). Cancer Res 71:S5-S11
23. Mukherjee A, Badal Y, Nguyen X-T et al (2011) Profiling the HER3/PI3K pathway in breast tumors using proximity-directed assays identifies correlations between protein complexes and phosphoproteins. PLoS ONE 6(1):e16443
24. Wallweber J, Chenna A, Ravanera R, et al (2013) Profiling HER3/ErbB3 activation in formalin-fixed, paraffin-embedded (FFPE) breast tumor samples that express high and low HER2/ErbB2 levels using proximity-based immunoassays. AACR Annual Meeting, April 2013; 3029
25. Larson J, Goodman L, Tan Y, DeFazio-Eli L, Paquet AC, Cook JW, Rivera A, Frankson K, Bose J, Chen L, Cheung J, Shi Y, Irwin S, Kiss L, Huang W, Utter S, Sherwood T, Bates M, Weidler J, Parry G, Winslow J, Petropoulos CJ, Whitcomb J (2010) Analytical validation of a highly sensitive, accurate, and reproducible assay (HERmarkTM) for the measurement of HER2 total protein and HER2 homodimers in FFPE breast cancer tumor specimens. Pathol Res Int 2010: article ID 814176
26. Shi Y, Huang W, Tan Y et al (2009) A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue. Diagn Mol Pathol 18:11-21
27. Bates M, Sperinde J, Kostler WJ et al (2011) Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab. Ann Oncol 22:2014-2020
28. Sperinde J, Jin X, Banerjee J et al (2010) Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients. Clin Cancer Res 16:4226-4235
29. Lipton A, Kostler WJ, Leitzel K et al (2010) Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab. Cancer 116:5168-5178
30. Therneau T, Atkinson B (2011) rpart: recursive partitioning. R package version 3.1-50. http://CRAN.R-project.org/package=rpart
31. Joensuu H, Sperinde J, Leinonen M et al (2011) Very high quantitative tumor HER2 content and outcome in early breast cancer. Ann Oncol 22:2007-2013